Ipsen
Highly Engaged Employees
Manufacturing · France · 5K - 10K Employees
View Company Info for Free
Overview
Headquarters
70 Rue Balard, Paris, Île-de-France, 750...Phone Number
+33 158335000Website
www.ipsen.comRevenue
$4.4 BillionStock Symbol
IPNIndustry
About Ipsen
Ipsen Org Chart
Is Ipsen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Ipsen is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Ipsen
Click to see if Ipsen had a recent Job posting/layoffs
Ipsen, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Ipsen launches new products
Funding: Get notified immidiatlly once Ipsen has new funding data
Earning: See what the market has to say on Ipsen recently announced quarterly report
Check if Ipsen has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Ipsen
Find 3 more new buyers
Company Profile Activity
Activity Insights
Ipsen is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ipsen is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ipsen.
Ipsen Tech Stack
A closer look at the technologies used by Ipsen
Most Recent Scoops
Ipsen News & Media
Ipsen S.A. (IPSEY) Q2 2026 Earnings Call Transcript
Ipsen S.A. (IPSEY) Q2 2026 Earnings Call July 30, 2026 8:00 AM EDTCompany ParticipantsDavid Loew - MD, CEO & DirectorAymeric Le Chatelier - Executive VP...Ipsen nominates Catherine Bradley to its Board of Directors as independent Director
Ipsen appoints Catherine Bradley as independent Director to its Board of DirectorsIPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2026
Aggregated presentation by day and by marketIpsen provides update on Phase III BOLD trial in biliary atresia
PARIS, FRANCE, 24 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Phase III BOLD trial evaluating Bylvay versus placebo for patients living with biliary atresia (BA) who have already undergone a Kasai hepatoportoenterostomy (HPE) did not meet the primary endpoint of improvement in native liver survival vs placebo. Current topline data is in line with the well-established safety profile of odevixibat in approved indications. Characterized as a rapidly progressive and comple
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ipsen
Founded in 1929 and headquartered in Boulogne, France, Ipsen Pharma is a global biopharmaceutical group focused on specialty care. The Group develops and commercializes medicines in therapeutic areas including oncology, neuroscience, and rare diseases.... Read More